{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T16:14:47Z","timestamp":1788106487094,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020604","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020604","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014091","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019189","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Blood pressure (BP) control is a Class I recommendation for the management of heart failure with preserved ejection fraction (HFpEF); however, evidence supporting systolic BP (SBP) targets remains limited. We investigated associations between BP control and subsequent outcomes in patients with HF with mildly reduced EF (HFmrEF)\/HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We pooled TOPCAT (Americas), PARAGON-HF, DELIVER, and FINEARTS-HF, which tested spironolactone, sacubitril\/valsartan, dapagliflozin, and finerenone, respectively, versus placebo or active control in patients with HF and an LVEF &amp;gt;40% (DELIVER), \u226540% (FINEARTS-HF), or \u226545% (TOPCAT-Americas, PARAGON-HF). Daily BPs were estimated by interpolation from standardized office measurements obtained at randomization and prespecified visits. Time in target range (TIR) was the percentage of the first year after randomization during which SBP was 110\u2013&amp;lt;130 mmHg. Continuous associations between TIR and subsequent risk of HF hospitalization or cardiovascular death, its individual components, and all-cause death was assessed using landmark Cox proportional hazards models with linear splines, adjusted for baseline cardiovascular risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 17,788 patients (mean age 72\u00b19 years; 47% women; mean baseline SBP 129\u00b115 mmHg), the median TIR was 38% (\u2248139 days). Randomization to active therapies increased TIR by 2% (95% CI: \u22122 to 6) with spironolactone, 7% (5 to 9) with sacubitril\/valsartan, 2% (0 to 4) with dapagliflozin, and 3% (1 to 5) with finerenone. Higher TIR was associated with lower subsequent risk of the composite outcome (P=0.021), primarily driven by lower HF hospitalization risk (P=0.007); associations with cardiovascular death and all-cause death were not significant. Sensitivity analyses using stricter (120\u2013&amp;lt;130 mmHg) or more liberal ranges (100\u2013&amp;lt;130 and 120\u2013&amp;lt;140 mmHg) yielded qualitatively similar findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with HFmrEF\/HFpEF, BP control during the first year was associated with a lower subsequent risk of HF hospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trials registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov ID NCT00094302 (TOPCAT), NCT01920711 (PARAGON-HF), NCT03619213 (DELIVER), NCT04435626 (FINEARTS-HF)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag245","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:29:59Z","timestamp":1786706999000},"source":"Crossref","is-referenced-by-count":0,"title":["Time in blood pressure range and cardiovascular outcomes in HFmrEF\/HFpEF: a pooled participant-level analysis of four large-scale trials"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-6505","authenticated-orcid":false,"given":"Henri","family":"Lu","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis St, Boston, MA 02115 ,","place":["USA"]},{"name":"Division of Cardiology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL) , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L","family":"Claggett","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis St, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Ostrominski","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis St, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis St, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Michigan School of Medicine, Ann Arbor , MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-5317","authenticated-orcid":false,"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9597","authenticated-orcid":false,"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis St, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis St, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , 75 Francis St, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"2026083011312520700_xuag245-B1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.hfc.2007.10.001","article-title":"Ventricular-vascular interaction in heart failure","volume":"4","author":"Borlaug","year":"2008","journal-title":"Heart Fail Clin"},{"key":"2026083011312520700_xuag245-B2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1161\/HYPERTENSIONAHA.114.03449","article-title":"Arterial stiffness and hypertension: chicken or egg?","volume":"64","author":"Mitchell","year":"2014","journal-title":"Hypertension"},{"key":"2026083011312520700_xuag245-B3","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026083011312520700_xuag245-B4","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026083011312520700_xuag245-B5","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jacc.2024.11.007","article-title":"Systolic blood pressure and pulse pressure in heart failure: pooled participant-level analysis of 4 trials","volume":"85","author":"Lu","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026083011312520700_xuag245-B6","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","article-title":"Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril\/valsartan","volume":"75","author":"Selvaraj","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026083011312520700_xuag245-B7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ejheart.2005.07.006","article-title":"Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program","volume":"8","author":"Mitchell","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"2026083011312520700_xuag245-B8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41569-022-00690-0","article-title":"Blood pressure and its variability: classic and novel measurement techniques","volume":"19","author":"Schutte","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2026083011312520700_xuag245-B9","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jacc.2021.01.014","article-title":"Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension","volume":"77","author":"Fatani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026083011312520700_xuag245-B10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/HYPERTENSIONAHA.124.24013","article-title":"Time in target range for blood pressure and adverse health outcomes: a systematic review","volume":"82","author":"Wang","year":"2025","journal-title":"Hypertension"},{"key":"2026083011312520700_xuag245-B11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1161\/HYPERTENSIONAHA.122.20141","article-title":"Systolic blood pressure time in target range and major adverse kidney and cardiovascular events","volume":"80","author":"Buckley","year":"2023","journal-title":"Hypertension"},{"key":"2026083011312520700_xuag245-B12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022765","article-title":"Time in target range for systolic blood pressure and cardiovascular outcomes in patients with heart failure with preserved ejection fraction","volume":"11","author":"Huang","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026083011312520700_xuag245-B13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026083011312520700_xuag245-B14","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026083011312520700_xuag245-B15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026083011312520700_xuag245-B16","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026083011312520700_xuag245-B17","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026083011312520700_xuag245-B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026083011312520700_xuag245-B19","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1002\/ejhf.3706","article-title":"Longitudinal blood pressure and cardiovascular outcomes in heart failure: an individual patient data pooling analysis of clinical trials","volume":"27","author":"Li","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026083011312520700_xuag245-B20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.cardfail.2009.03.006","article-title":"Central aortic stiffness is increased in patients with heart failure and preserved ejection fraction","volume":"15","author":"Desai","year":"2009","journal-title":"J Card Fail"},{"key":"2026083011312520700_xuag245-B21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jchf.2016.02.017","article-title":"Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction","volume":"4","author":"Kapoor","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2026083011312520700_xuag245-B22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamacardio.2025.0860","article-title":"Mode of death in patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF randomized clinical trial","volume":"10","author":"Desai","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026083011312520700_xuag245-B23","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/jamacardio.2022.3736","article-title":"Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction: a participant-level pooled analysis of DAPA-HF and DELIVER","volume":"7","author":"Desai","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026083011312520700_xuag245-B24","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0140-6736(18)31880-4","article-title":"Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial","volume":"392","author":"Koehler","year":"2018","journal-title":"Lancet"},{"key":"2026083011312520700_xuag245-B25","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/j.jchf.2024.08.007","article-title":"Mineralocorticoid antagonism in heart failure: established and emerging therapeutic role","volume":"12","author":"Chang","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026083011312520700_xuag245-B26","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"2026083011312520700_xuag245-B27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"key":"2026083011312520700_xuag245-B28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026083011312520700_xuag245-B29","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1093\/eurheartj\/ehad389","article-title":"Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction","volume":"44","author":"Pandey","year":"2023","journal-title":"Eur Heart J"},{"key":"2026083011312520700_xuag245-B30","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/HJH.0b013e3283516499","article-title":"Impact of lower achieved blood pressure on outcomes in hypertensive patients","volume":"30","author":"Okin","year":"2012","journal-title":"J Hypertens"},{"key":"2026083011312520700_xuag245-B31","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1161\/HYPERTENSIONAHA.123.21454","article-title":"Middle-aged and older patients with left ventricular hypertrophy: higher mortality with drug treated systolic blood pressure below 130 mm Hg","volume":"80","author":"Heimark","year":"2023","journal-title":"Hypertension"},{"key":"2026083011312520700_xuag245-B32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S2213-8587(18)30099-8","article-title":"Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials","volume":"6","author":"Beddhu","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026083011312520700_xuag245-B33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","article-title":"Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial","volume":"404","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"2026083011312520700_xuag245-B34","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","article-title":"Intensive blood-pressure control in patients with type 2 diabetes","volume":"392","author":"Bi","year":"2025","journal-title":"N Engl J Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag245\/70651941\/xuag245.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag245\/70651941\/xuag245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T15:31:35Z","timestamp":1788103895000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article\/doi\/10.1093\/ejhf\/xuag245\/8761786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag245","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]},"article-number":"xuag245"}}